Cargando…
Recurrent Transient Asymptomatic Pulmonary Opacity with Long-Term Afatinib: A Case Report
Afatinib is the second generation EGFR-TKI. Recently, transient asymptomatic pulmonary opacity (TAPO) was reported in EGFR-mutation harboring NSCLC receiving osimertinib. However, TAPO related to other EGFR-TKI has not been reported. Here, we reported a case of TAPO related to afatinib in lung adeno...
Autores principales: | Watanabe, Keisuke, Kobayashi, Nobuaki, Kaneko, Takeshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051041/ https://www.ncbi.nlm.nih.gov/pubmed/37008833 http://dx.doi.org/10.1159/000529894 |
Ejemplares similares
-
EGFR-mutant Non-small Cell Lung Cancer Accompanied by Transient Asymptomatic Pulmonary Opacities Successfully Treated with “Stop-And-Go” Osimertinib
por: Kobayashi, Keigo, et al.
Publicado: (2017) -
Transient asymptomatic pulmonary opacities in a patient with MET exon 14 skipping non‐small cell lung cancer: A case report
por: Ikeo, Satoshi, et al.
Publicado: (2023) -
Afatinib use in recurrent epithelial ovarian carcinoma
por: Shepherd-Littlejohn, Amanda L., et al.
Publicado: (2019) -
Genomic Analysis of Tumors from Patients with Glioblastoma with Long-Term Response to Afatinib
por: Owen, Scott, et al.
Publicado: (2022) -
Transient Neonatal Diabetes Mellitus followed by recurrent asymptomatic hypoglycaemia: a case report
por: Priyadarshi, Archana, et al.
Publicado: (2015)